Ian Sanderson
About Ian Sanderson
Ian Sanderson serves as the Chief Financial Officer at Nimbus Therapeutics, where he has worked since 2021. He has extensive experience in the pharmaceuticals industry, having held various leadership roles, including CFO positions at Boston Pharmaceuticals and Catabasis Pharmaceuticals.
Work at Nimbus Therapeutics
Ian Sanderson has served as the Chief Financial Officer at Nimbus Therapeutics since 2021. In this role, he oversees the financial operations and strategic financial planning of the company, which is based in Cambridge, Massachusetts. His responsibilities include managing financial risks, financial reporting, and ensuring the company’s financial health as it develops innovative therapies.
Previous Experience in Pharmaceuticals
Before joining Nimbus Therapeutics, Ian Sanderson held the position of Chief Financial Officer at Boston Pharmaceuticals from 2016 to 2021. He also served as CFO at Catabasis Pharmaceuticals from 2013 to 2016. His extensive experience in the pharmaceutical industry includes roles at Cowen and Company as Managing Director of Institutional Research and as a Senior Associate at Houlihan Lokey.
Education and Expertise
Ian Sanderson earned a Bachelor of Arts in Political Economy from Williams College, where he studied from 1979 to 1983. He furthered his education by obtaining a Master of Business Administration from The Wharton School, studying from 1987 to 1989. His expertise includes structuring partnerships in the pharmaceutical sector and designing small molecule compounds aimed at addressing complex human diseases.
Background in Finance and Research
Ian Sanderson has a strong background in equity research and venture capital, particularly within the pharmaceuticals industry. His career began as an Associate at Cambridge Associates, followed by significant roles that contributed to his financial acumen and understanding of the pharmaceutical landscape. His experience spans over three decades, showcasing his commitment to advancing healthcare through financial leadership.